List of Publications
There are numbers of autism related research can be found in Malaysia that generally focus on the ASD, learning disorder, communication aids, therapy and many more. The list of publications is provided below:
- Click this to search using keyword determined by the user.
- It will lead to a new web page with a text search box.
- Type your keyword in the search box
- Click on Keyword to search for any publication. Bigger words indicate the most used tags and smaller words indicate the least used.
- Click on dropdown buttons to choose any years, types of publications or authors of your choice.
- Click on underlined words in the publication detail to view more information.
2019 |
Mohamad, F H; Has, A T C The α5-Containing GABA A Receptors—a Brief Summary Journal Article Journal of Molecular Neuroscience, 67 (2), pp. 343-351, 2019, ISSN: 08958696, (cited By 1). Abstract | Links | BibTeX | Tags: 4 Aminobutyric Acid, 4 Aminobutyric Acid A Receptor, Alpha5 Containing 4 Aminobutyric Acid A Receptor, Animals, Autism, Brain, Cognitive Defect, Cognitive Dysfunction, Drug Effect, GABA Agents, GABA-A, GABAergic Receptor Affecting Agent, Genetics, Human, Metabolism, Nonhuman, Protein Subunit, Protein Subunits, Receptors, Review, Schizophrenia, Unclassified Drug @article{Mohamad2019343, title = {The α5-Containing GABA A Receptors—a Brief Summary}, author = {F H Mohamad and A T C Has}, url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85059596842&doi=10.1007%2fs12031-018-1246-4&partnerID=40&md5=7b2ba0dc86c6c3f890f226cad8195ee5}, doi = {10.1007/s12031-018-1246-4}, issn = {08958696}, year = {2019}, date = {2019-01-01}, journal = {Journal of Molecular Neuroscience}, volume = {67}, number = {2}, pages = {343-351}, publisher = {Springer New York LLC}, abstract = {GABA A receptors are the major inhibitory neurotransmitter receptor in the human brain. The receptors are assembled from combination of protein subunits in pentameric complex which may consist of α1–6, β1–3, γ1–3, ρ1–3, δ, ε, θ, or π subunits. There are a theoretical > 150,000 possible assemblies and arrangements of GABA A subunits, although only a few combinations have been found in human with the most dominant consists of 2α1, 2β2, and 1γ2 in a counterclockwise arrangement as seen from the synaptic cleft. The receptors also possess binding sites for various unrelated substances including benzodiazepines, barbiturates, and anesthetics. The α5-containing GABA A Rs only make up ≤ 5% of the entire receptor population, but up to 25% of the receptor subtype is located in the crucial learning and memory-associated area of the brain—the hippocampus, which has ignited myriads of hypotheses and theories in regard to its role. As well as exhibiting synaptic phasic inhibition, the α5-containing receptors are also extrasynaptic and mediate tonic inhibition with continuously occurring smaller amplitude. Studies on negative-allosteric modulators for reducing this tonic inhibition have been shown to enhance learning and memory in neurological disorders such as schizophrenia, Down syndrome, and autism with a possible alternative benzodiazepine binding site. Therefore, a few α5 subunit-specific compounds have been developed to address these pharmacological needs. With its small population, the α5-containing receptors could be the key and also the answer for many untreated cognitive dysfunctions and disorders. © 2019, Springer Science+Business Media, LLC, part of Springer Nature.}, note = {cited By 1}, keywords = {4 Aminobutyric Acid, 4 Aminobutyric Acid A Receptor, Alpha5 Containing 4 Aminobutyric Acid A Receptor, Animals, Autism, Brain, Cognitive Defect, Cognitive Dysfunction, Drug Effect, GABA Agents, GABA-A, GABAergic Receptor Affecting Agent, Genetics, Human, Metabolism, Nonhuman, Protein Subunit, Protein Subunits, Receptors, Review, Schizophrenia, Unclassified Drug}, pubstate = {published}, tppubtype = {article} } GABA A receptors are the major inhibitory neurotransmitter receptor in the human brain. The receptors are assembled from combination of protein subunits in pentameric complex which may consist of α1–6, β1–3, γ1–3, ρ1–3, δ, ε, θ, or π subunits. There are a theoretical > 150,000 possible assemblies and arrangements of GABA A subunits, although only a few combinations have been found in human with the most dominant consists of 2α1, 2β2, and 1γ2 in a counterclockwise arrangement as seen from the synaptic cleft. The receptors also possess binding sites for various unrelated substances including benzodiazepines, barbiturates, and anesthetics. The α5-containing GABA A Rs only make up ≤ 5% of the entire receptor population, but up to 25% of the receptor subtype is located in the crucial learning and memory-associated area of the brain—the hippocampus, which has ignited myriads of hypotheses and theories in regard to its role. As well as exhibiting synaptic phasic inhibition, the α5-containing receptors are also extrasynaptic and mediate tonic inhibition with continuously occurring smaller amplitude. Studies on negative-allosteric modulators for reducing this tonic inhibition have been shown to enhance learning and memory in neurological disorders such as schizophrenia, Down syndrome, and autism with a possible alternative benzodiazepine binding site. Therefore, a few α5 subunit-specific compounds have been developed to address these pharmacological needs. With its small population, the α5-containing receptors could be the key and also the answer for many untreated cognitive dysfunctions and disorders. © 2019, Springer Science+Business Media, LLC, part of Springer Nature. |
Khan, N A; Soopramanien, M; Siddiqui, R Crocodiles and alligators: Physicians’ answer to cancer? Journal Article Current Oncology, 26 (3), pp. 186, 2019, ISSN: 11980052, (cited By 1). Links | BibTeX | Tags: Allergic Disease, Alligators and Crocodiles, Animal Product, Animals, Antineoplastic Activity, Antineoplastic Agent, Article, Atopic Dermatitis, Autism, Cancer Growth, Cancer Therapy, Carcinogen, Contaminated Organism, Crocodilian, End Cretaceous Mass Extinction, Environmental Factor, Environmental Stress, Gastrointestinal Microbiome, Health Behaviour, Heavy Metal, Human, Immune System, Inflammatory Bowel Disease, Intestine Flora, Longevity, Metabolic Disorder, Microbiology, Neoplasm, Neoplasms, Nerve Cell Differentiation, Physician, Schizophrenia, Survival Analysis, Terminal Disease @article{Khan2019186, title = {Crocodiles and alligators: Physicians’ answer to cancer?}, author = {N A Khan and M Soopramanien and R Siddiqui}, url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85069313377&doi=10.3747%2fco.26.4855&partnerID=40&md5=6a266208d5fe14a1c888bb1db397d744}, doi = {10.3747/co.26.4855}, issn = {11980052}, year = {2019}, date = {2019-01-01}, journal = {Current Oncology}, volume = {26}, number = {3}, pages = {186}, publisher = {Multimed Inc.}, note = {cited By 1}, keywords = {Allergic Disease, Alligators and Crocodiles, Animal Product, Animals, Antineoplastic Activity, Antineoplastic Agent, Article, Atopic Dermatitis, Autism, Cancer Growth, Cancer Therapy, Carcinogen, Contaminated Organism, Crocodilian, End Cretaceous Mass Extinction, Environmental Factor, Environmental Stress, Gastrointestinal Microbiome, Health Behaviour, Heavy Metal, Human, Immune System, Inflammatory Bowel Disease, Intestine Flora, Longevity, Metabolic Disorder, Microbiology, Neoplasm, Neoplasms, Nerve Cell Differentiation, Physician, Schizophrenia, Survival Analysis, Terminal Disease}, pubstate = {published}, tppubtype = {article} } |
2018 |
Paudel, Y N; Shaikh, M F; Shah, S; Kumari, Y; Othman, I Role of inflammation in epilepsy and neurobehavioral comorbidities: Implication for therapy Journal Article European Journal of Pharmacology, 837 , pp. 145-155, 2018, ISSN: 00142999, (cited By 14). Abstract | Links | BibTeX | Tags: 3 Dioxygenase, Acetylsalicylic Acid, Adalimumab, Anakinra, Animals, Anti-Inflammatory Agents, Anxiety, Autacoid, Autism, Autism Spectrum Disorders, Behaviour Disorder, Belnacasan, Celecoxib, Cognition, Comorbidity, Complication, Cyclooxygenase 2, Cyclooxygenase 2 Inhibitor, Cytokine, Cytokines, Depression, Dexmedetomidine, Disease Association, Dopaminergic Transmission, Electroencephalogram, Electroencephalography, Epilepsy, Epileptogenesis, Esculetin, High Mobility Group B1 Protein, Human, Ibuprofen, Icariin, IImmunoglobulin Enhancer Binding Protein, Immunology, Indoleamine 2, Inflammation, Inflammation Mediators, Infliximab, Interleukin 1beta, Interleukin 6, Minocycline, Nerve Cell Plasticity, Nervous System Development, Nervous System Inflammation, Neuroendocrine Regulation, Neurotransmitter Release, Nonhuman, Palmidrol, Paracetamol, Physiology, Priority Journal, Prostaglandin E2, Psychology, Review, SC 51089, Schizophrenia, Toll-Like Receptor 4, Transforming Growth Factor Beta, Tryptophan Hydroxylase, Tumor Necrosis Factor, Unclassified Drug @article{Paudel2018145, title = {Role of inflammation in epilepsy and neurobehavioral comorbidities: Implication for therapy}, author = {Y N Paudel and M F Shaikh and S Shah and Y Kumari and I Othman}, url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85053082063&doi=10.1016%2fj.ejphar.2018.08.020&partnerID=40&md5=27ff0199bae72f156425637a7ad02228}, doi = {10.1016/j.ejphar.2018.08.020}, issn = {00142999}, year = {2018}, date = {2018-01-01}, journal = {European Journal of Pharmacology}, volume = {837}, pages = {145-155}, publisher = {Elsevier B.V.}, abstract = {Epilepsy is a devastating condition affecting around 70 million people worldwide. Moreover, the quality of life of people with epilepsy (PWE) is worsened by a series of comorbidities. The neurobehavioral comorbidities discussed herein share a reciprocal and complex relationship with epilepsy, which ultimately complicates the treatment process in PWE. Understanding the mechanistic pathway by which these comorbidities are associated with epilepsy might be instrumental in developing therapeutic interventions. Inflammatory cytokine signaling in the brain regulates important brain functions including neurotransmitter metabolism, neuroendocrine function, synaptic plasticity, dopaminergic transmission, the kynurenine pathway, and affects neurogenesis as well as the neural circuitry of moods. In this review, we hypothesize that the complex relationship between epilepsy and its related comorbidities (cognitive impairment, depression, anxiety, autism, and schizophrenia) can be unraveled through the inflammatory mechanism that plays a prominent role in all these individual conditions. An ample amount of evidence is available reporting the role of inflammation in epilepsy and all individual comorbid condition but their complex relationship with epilepsy has not yet been explored through the prospective of inflammatory pathway. Our review suggests that epilepsy and its neurobehavioral comorbidities are associated with elevated levels of several key inflammatory markers. This review also sheds light on the mechanistic association between epilepsy and its neurobehavioral comorbidities. Moreover, we analyzed several anti-inflammatory therapies available for epilepsy and its neurobehavioral comorbidities. We suggest, these anti-inflammatory therapies might be a possible intervention and could be a promising strategy for preventing epileptogenesis and its related neurobehavioral comorbidities. © 2018 Elsevier B.V.}, note = {cited By 14}, keywords = {3 Dioxygenase, Acetylsalicylic Acid, Adalimumab, Anakinra, Animals, Anti-Inflammatory Agents, Anxiety, Autacoid, Autism, Autism Spectrum Disorders, Behaviour Disorder, Belnacasan, Celecoxib, Cognition, Comorbidity, Complication, Cyclooxygenase 2, Cyclooxygenase 2 Inhibitor, Cytokine, Cytokines, Depression, Dexmedetomidine, Disease Association, Dopaminergic Transmission, Electroencephalogram, Electroencephalography, Epilepsy, Epileptogenesis, Esculetin, High Mobility Group B1 Protein, Human, Ibuprofen, Icariin, IImmunoglobulin Enhancer Binding Protein, Immunology, Indoleamine 2, Inflammation, Inflammation Mediators, Infliximab, Interleukin 1beta, Interleukin 6, Minocycline, Nerve Cell Plasticity, Nervous System Development, Nervous System Inflammation, Neuroendocrine Regulation, Neurotransmitter Release, Nonhuman, Palmidrol, Paracetamol, Physiology, Priority Journal, Prostaglandin E2, Psychology, Review, SC 51089, Schizophrenia, Toll-Like Receptor 4, Transforming Growth Factor Beta, Tryptophan Hydroxylase, Tumor Necrosis Factor, Unclassified Drug}, pubstate = {published}, tppubtype = {article} } Epilepsy is a devastating condition affecting around 70 million people worldwide. Moreover, the quality of life of people with epilepsy (PWE) is worsened by a series of comorbidities. The neurobehavioral comorbidities discussed herein share a reciprocal and complex relationship with epilepsy, which ultimately complicates the treatment process in PWE. Understanding the mechanistic pathway by which these comorbidities are associated with epilepsy might be instrumental in developing therapeutic interventions. Inflammatory cytokine signaling in the brain regulates important brain functions including neurotransmitter metabolism, neuroendocrine function, synaptic plasticity, dopaminergic transmission, the kynurenine pathway, and affects neurogenesis as well as the neural circuitry of moods. In this review, we hypothesize that the complex relationship between epilepsy and its related comorbidities (cognitive impairment, depression, anxiety, autism, and schizophrenia) can be unraveled through the inflammatory mechanism that plays a prominent role in all these individual conditions. An ample amount of evidence is available reporting the role of inflammation in epilepsy and all individual comorbid condition but their complex relationship with epilepsy has not yet been explored through the prospective of inflammatory pathway. Our review suggests that epilepsy and its neurobehavioral comorbidities are associated with elevated levels of several key inflammatory markers. This review also sheds light on the mechanistic association between epilepsy and its neurobehavioral comorbidities. Moreover, we analyzed several anti-inflammatory therapies available for epilepsy and its neurobehavioral comorbidities. We suggest, these anti-inflammatory therapies might be a possible intervention and could be a promising strategy for preventing epileptogenesis and its related neurobehavioral comorbidities. © 2018 Elsevier B.V. |
Thu, Ei H; Hussain, Z; Shuid, A N Current Drug Targets, 19 (8), pp. 865-876, 2018, ISSN: 13894501, (cited By 2). Abstract | Links | BibTeX | Tags: Amisulpride, Amitriptyline, Animals, Antipsychotic Agents, Anxiety, Aripiprazole, Autism, Bioavailability, Biological Availability, Bipolar Disorder, Buspirone, Chemistry, Clonazepam, Clozapine, Depression, Diazepam, Drug Delivery System, Drug Delivery Systems, Duloxetine, Half Life Time, Half-Life, Health Care, Human, Iloperidone, In Vitro Study, In Vivo Study, Mental Disease, Mental Disorders, Midazolam, Nanotechnology, Neuroleptic Agent, Olanzapine, Pathophysiology, Permeability, Physical Chemistry, Psychosis, Review, Risperidone, Schizophrenia, Solubility, Sulpiride, Treatment Outcome, Venlafaxine, Ziprasidone @article{EiThu2018865, title = {New insight in improving therapeutic efficacy of antipsychotic agents: An overview of improved in vitro and in vivo performance, efficacy upgradation and future prospects}, author = {H Ei Thu and Z Hussain and A N Shuid}, url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85048981535&doi=10.2174%2f1389450117666161125174625&partnerID=40&md5=d32e5bc9766ff9d68dd79f082b9ca4bc}, doi = {10.2174/1389450117666161125174625}, issn = {13894501}, year = {2018}, date = {2018-01-01}, journal = {Current Drug Targets}, volume = {19}, number = {8}, pages = {865-876}, publisher = {Bentham Science Publishers B.V.}, abstract = {Psychotic disorders are recognized as severe mental disorders that rigorously affect pa-tient’s personality, critical thinking, and perceptional ability. High prevalence, global dissemination and limitations of conventional pharmacological approaches compel a significant burden to the patient, medical professionals and the healthcare system. To date, numerous orally administered therapies are available for the management of depressive disorders, schizophrenia, anxiety, bipolar disorders and autism spectrum problems. However, poor water solubility, erratic oral absorption, extensive first-pass metabolism, low oral bioavailability and short half-lives are the major factors which limit the pharmaceutical significance and therapeutic feasibility of these agents. In recent decades, nanotechnology-based delivery systems have gained remarkable attention of the researchers to mitigate the pharmaceutical issues related to the antipsychotic therapies and to optimize their oral drug delivery, therapeutic outcomes, and patient compliance. Therefore, the present review was aimed to summarize the available in vitro and in vivo evidences signifying the pharmaceutical importance of the advanced delivery systems in improving the aqueous solubility, transmembrane permeability, oral bioavailability and therapeutic outcome of the antipsychotic agents. © 2018 Bentham Science Publishers.}, note = {cited By 2}, keywords = {Amisulpride, Amitriptyline, Animals, Antipsychotic Agents, Anxiety, Aripiprazole, Autism, Bioavailability, Biological Availability, Bipolar Disorder, Buspirone, Chemistry, Clonazepam, Clozapine, Depression, Diazepam, Drug Delivery System, Drug Delivery Systems, Duloxetine, Half Life Time, Half-Life, Health Care, Human, Iloperidone, In Vitro Study, In Vivo Study, Mental Disease, Mental Disorders, Midazolam, Nanotechnology, Neuroleptic Agent, Olanzapine, Pathophysiology, Permeability, Physical Chemistry, Psychosis, Review, Risperidone, Schizophrenia, Solubility, Sulpiride, Treatment Outcome, Venlafaxine, Ziprasidone}, pubstate = {published}, tppubtype = {article} } Psychotic disorders are recognized as severe mental disorders that rigorously affect pa-tient’s personality, critical thinking, and perceptional ability. High prevalence, global dissemination and limitations of conventional pharmacological approaches compel a significant burden to the patient, medical professionals and the healthcare system. To date, numerous orally administered therapies are available for the management of depressive disorders, schizophrenia, anxiety, bipolar disorders and autism spectrum problems. However, poor water solubility, erratic oral absorption, extensive first-pass metabolism, low oral bioavailability and short half-lives are the major factors which limit the pharmaceutical significance and therapeutic feasibility of these agents. In recent decades, nanotechnology-based delivery systems have gained remarkable attention of the researchers to mitigate the pharmaceutical issues related to the antipsychotic therapies and to optimize their oral drug delivery, therapeutic outcomes, and patient compliance. Therefore, the present review was aimed to summarize the available in vitro and in vivo evidences signifying the pharmaceutical importance of the advanced delivery systems in improving the aqueous solubility, transmembrane permeability, oral bioavailability and therapeutic outcome of the antipsychotic agents. © 2018 Bentham Science Publishers. |
2017 |
Hakim, N H A; Majlis, B Y; Suzuki, H; Tsukahara, T Neuron-specific splicing Journal Article BioScience Trends, 11 (1), pp. 16-22, 2017, ISSN: 18817815, (cited By 0). Abstract | Links | BibTeX | Tags: Alternative RNA Splicing, Alternative Splicing, Animals, Antibody Specificity, Biological, Biological Model, Diseases, Genetics, Human, Metabolism, Models, Nerve Cell, Neurons, Organ Specificity, RNA Splicing @article{Hakim201716, title = {Neuron-specific splicing}, author = {N H A Hakim and B Y Majlis and H Suzuki and T Tsukahara}, url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85014435502&doi=10.5582%2fbst.2016.01169&partnerID=40&md5=8a5044dbf3b905fc2553520a048bcd59}, doi = {10.5582/bst.2016.01169}, issn = {18817815}, year = {2017}, date = {2017-01-01}, journal = {BioScience Trends}, volume = {11}, number = {1}, pages = {16-22}, publisher = {International Advancement Center for Medicine and Health Research Co., Ltd.}, abstract = {During pre-mRNA splicing events, introns are removed from the pre-mRNA, and the remaining exons are connected together to form a single continuous molecule. Alternative splicing is a common mechanism for the regulation of gene expression in eukaryotes. More than 90% of human genes are known to undergo alternative splicing. The most common type of alternative splicing is exon skipping, which is also known as cassette exon. Other known alternative splicing events include alternative 5' splice sites, alternative 3' splice sites, intron retention, and mutually exclusive exons. Alternative splicing events are controlled by regulatory proteins responsible for both positive and negative regulation. In this review, we focus on neuronal splicing regulators and discuss several notable regulators in depth. In addition, we have also included an example of splicing regulation mediated by the RBFox protein family. Lastly, as previous studies have shown that a number of splicing factors are associated with neuronal diseases such as Alzheime's disease (AD) and Autism spectrum disorder (ASD), here we consider their importance in neuronal diseases wherein the underlying mechanisms have yet to be elucidated.}, note = {cited By 0}, keywords = {Alternative RNA Splicing, Alternative Splicing, Animals, Antibody Specificity, Biological, Biological Model, Diseases, Genetics, Human, Metabolism, Models, Nerve Cell, Neurons, Organ Specificity, RNA Splicing}, pubstate = {published}, tppubtype = {article} } During pre-mRNA splicing events, introns are removed from the pre-mRNA, and the remaining exons are connected together to form a single continuous molecule. Alternative splicing is a common mechanism for the regulation of gene expression in eukaryotes. More than 90% of human genes are known to undergo alternative splicing. The most common type of alternative splicing is exon skipping, which is also known as cassette exon. Other known alternative splicing events include alternative 5' splice sites, alternative 3' splice sites, intron retention, and mutually exclusive exons. Alternative splicing events are controlled by regulatory proteins responsible for both positive and negative regulation. In this review, we focus on neuronal splicing regulators and discuss several notable regulators in depth. In addition, we have also included an example of splicing regulation mediated by the RBFox protein family. Lastly, as previous studies have shown that a number of splicing factors are associated with neuronal diseases such as Alzheime's disease (AD) and Autism spectrum disorder (ASD), here we consider their importance in neuronal diseases wherein the underlying mechanisms have yet to be elucidated. |
2015 |
Gallagher, D; Voronova, A; Zander, M A; Cancino, G I; Bramall, A; Krause, M P; Abad, C; Tekin, M; Neilsen, P M; Callen, D F; Scherer, S W; Keller, G M; Kaplan, D R; Walz, K; Miller, F D Ankrd11 is a chromatin regulator involved in autism that is essential for neural development Journal Article Developmental Cell, 32 (1), pp. 31-42, 2015, ISSN: 15345807, (cited By 52). Abstract | Links | BibTeX | Tags: Acetylation, Animal Behavior, Animal Cell, Animals, Ankrd11 Protein, Ankyrin, Ankyrin Repeat Domain Containing Protein 11, Article, Autism, Autism Spectrum Disorders, Behaviour, Biological Marker, Blotting, Brain Cell Culture, Cell Culture, Cell Differentiation, Cell Proliferation, Cells, Chemistry, Chromatin, Chromatin Immunoprecipitation, Cultured, DNA Binding Protein, DNA Microarray, DNA-Binding Proteins, Enzyme Activity, Female, Gene, Gene Expression Profiling, Gene Targeting, Genetics, Histone, Histone Acetylation, Histone Acetyltransferase, Histone Deacetylase, Histone Deacetylase 3, Histone Deacetylases, Histones, Human, Human Cell, Immunoprecipitation, Messenger, Messenger RNA, Metabolism, Mice, Mouse, Murinae, Mus, Nerve Cell Differentiation, Nervous System Development, Neurogenesis, Nonhuman, Oligonucleotide Array Sequence Analysis, Pathology, Phenotype, Physiology, Point Mutation, Post-Translational, Priority Journal, Protein Expression, Protein Processing, Real-Time Polymerase Chain Reaction, Reverse Transcriptase Polymerase Chain Reaction, Reverse Transcription Polymerase Chain Reaction, RNA, Small Interfering, Small Interfering RNA, Unclassified Drug, Western, Western Blotting @article{Gallagher201531, title = {Ankrd11 is a chromatin regulator involved in autism that is essential for neural development}, author = {D Gallagher and A Voronova and M A Zander and G I Cancino and A Bramall and M P Krause and C Abad and M Tekin and P M Neilsen and D F Callen and S W Scherer and G M Keller and D R Kaplan and K Walz and F D Miller}, url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-84922343890&doi=10.1016%2fj.devcel.2014.11.031&partnerID=40&md5=ad7b8bd3ead790f092e1d8a276d4f25c}, doi = {10.1016/j.devcel.2014.11.031}, issn = {15345807}, year = {2015}, date = {2015-01-01}, journal = {Developmental Cell}, volume = {32}, number = {1}, pages = {31-42}, publisher = {Cell Press}, abstract = {Ankrd11 is a potential chromatin regulator implicated in neural development and autism spectrum disorder (ASD) with no known function in the brain. Here, we show that knockdown of Ankrd11 in developing murine or human cortical neural precursors caused decreased proliferation, reduced neurogenesis, andaberrant neuronal positioning. Similar cellular phenotypes and aberrant ASD-like behaviors were observed in Yoda mice carrying a point mutation inthe Ankrd11 HDAC-binding domain. Consistent with a role for Ankrd11 in histone acetylation, Ankrd11 was associated with chromatin and colocalized with HDAC3, and expression and histone acetylation of Ankrd11 target genes were altered in Yoda neural precursors. Moreover, the Ankrd11 knockdown-mediated decrease in precursor proliferation was rescued by inhibiting histone acetyltransferase activity or expressing HDAC3. Thus, Ankrd11 is a crucial chromatin regulator that controls histone acetylation and gene expression during neural development, thereby providing a likely explanation for its association with cognitive dysfunction and ASD. © 2015 Elsevier Inc.}, note = {cited By 52}, keywords = {Acetylation, Animal Behavior, Animal Cell, Animals, Ankrd11 Protein, Ankyrin, Ankyrin Repeat Domain Containing Protein 11, Article, Autism, Autism Spectrum Disorders, Behaviour, Biological Marker, Blotting, Brain Cell Culture, Cell Culture, Cell Differentiation, Cell Proliferation, Cells, Chemistry, Chromatin, Chromatin Immunoprecipitation, Cultured, DNA Binding Protein, DNA Microarray, DNA-Binding Proteins, Enzyme Activity, Female, Gene, Gene Expression Profiling, Gene Targeting, Genetics, Histone, Histone Acetylation, Histone Acetyltransferase, Histone Deacetylase, Histone Deacetylase 3, Histone Deacetylases, Histones, Human, Human Cell, Immunoprecipitation, Messenger, Messenger RNA, Metabolism, Mice, Mouse, Murinae, Mus, Nerve Cell Differentiation, Nervous System Development, Neurogenesis, Nonhuman, Oligonucleotide Array Sequence Analysis, Pathology, Phenotype, Physiology, Point Mutation, Post-Translational, Priority Journal, Protein Expression, Protein Processing, Real-Time Polymerase Chain Reaction, Reverse Transcriptase Polymerase Chain Reaction, Reverse Transcription Polymerase Chain Reaction, RNA, Small Interfering, Small Interfering RNA, Unclassified Drug, Western, Western Blotting}, pubstate = {published}, tppubtype = {article} } Ankrd11 is a potential chromatin regulator implicated in neural development and autism spectrum disorder (ASD) with no known function in the brain. Here, we show that knockdown of Ankrd11 in developing murine or human cortical neural precursors caused decreased proliferation, reduced neurogenesis, andaberrant neuronal positioning. Similar cellular phenotypes and aberrant ASD-like behaviors were observed in Yoda mice carrying a point mutation inthe Ankrd11 HDAC-binding domain. Consistent with a role for Ankrd11 in histone acetylation, Ankrd11 was associated with chromatin and colocalized with HDAC3, and expression and histone acetylation of Ankrd11 target genes were altered in Yoda neural precursors. Moreover, the Ankrd11 knockdown-mediated decrease in precursor proliferation was rescued by inhibiting histone acetyltransferase activity or expressing HDAC3. Thus, Ankrd11 is a crucial chromatin regulator that controls histone acetylation and gene expression during neural development, thereby providing a likely explanation for its association with cognitive dysfunction and ASD. © 2015 Elsevier Inc. |
2014 |
Karim, S; Mirza, Z; Kamal, M A; Abuzenadah, A M; Azhar, E I; Al-Qahtani, M H; Damanhouri, G A; Ahmad, F; Gan, S H; Sohrab, S S The role of viruses in neurodegenerative and neurobehavioral diseases Journal Article CNS and Neurological Disorders - Drug Targets, 13 (7), pp. 1213-1223, 2014, ISSN: 18715273, (cited By 12). Abstract | Links | BibTeX | Tags: Alzheimer Disease, Amyotrophic Lateral Sclerosis, Animals, Article, Autism, Beta Interferon, Borna Disease Virus, Cytomegalovirus, Degenerative Disease, Disease Association, Enterovirus, Epstein Barr virus, Hepatitis Virus, Herpes Simplex Virus, HIV Associated Dementia, Human, Immune System, Inflammation, Influenza Virus, Influenza Virus A H5N1, Mental Disease, Mental Disorders, Multiple Sclerosis, Nerve Cell Degeneration, Neurodegenerative Diseases, Nonhuman, Parkinson Disease, Pathophysiology, Picornavirus, Roseolovirus, Varicella Zoster Virus, Virology, Virus Infection, Virus Pathogenesis, Virus Transmission, West Nile Flavivirus @article{Karim20141213, title = {The role of viruses in neurodegenerative and neurobehavioral diseases}, author = {S Karim and Z Mirza and M A Kamal and A M Abuzenadah and E I Azhar and M H Al-Qahtani and G A Damanhouri and F Ahmad and S H Gan and S S Sohrab}, url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-84911396470&doi=10.2174%2f187152731307141015122638&partnerID=40&md5=7564c64b2fe5d0737f83e65e1fdff60a}, doi = {10.2174/187152731307141015122638}, issn = {18715273}, year = {2014}, date = {2014-01-01}, journal = {CNS and Neurological Disorders - Drug Targets}, volume = {13}, number = {7}, pages = {1213-1223}, publisher = {Bentham Science Publishers B.V.}, abstract = {Neurodegenerative and neurobehavioral diseases may be caused by chronic and neuropathic viral infections and may result in a loss of neurons and axons in the central nervous system that increases with age. To date, there is evidence of systemic viral infections that occur with some neurodegenerative conditions such as Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis, multiple sclerosis, autism spectrum disorders, and HIV-associated neurocognitive disorders. With increasing lifespan, the incidence of neurodegenerative diseases increases consistently. Neurodegenerative diseases affect approximately 37 million people worldwide and are an important cause of mortality. In addition to established non-viral-induced reasons for neurodegenerative diseases, neuropathic infections and viruses associated with neurodegenerative diseases have been proposed. Neuronal degeneration can be either directly or indirectly affected by viral infection. Viruses that attack the human immune system can also affect the nervous system and interfere with classical pathways of neurodegenerative diseases. Viruses can enter the central nervous system, but the exact mechanism cannot be understood well. Various studies have supported viral- and non-viral-mediated neurodegeneration at the cellular, molecular, genomic and proteomic levels. The main focus of this review is to illustrate the association between viral infections and both neurodegenerative and neurobehavioral diseases, so that the possible mechanism and pathway of neurodegenerative diseases can be better explained. This information will strengthen new concepts and ideas for neurodegenerative and neurobehavioral disease treatment. © 2014 Bentham Science Publishers.}, note = {cited By 12}, keywords = {Alzheimer Disease, Amyotrophic Lateral Sclerosis, Animals, Article, Autism, Beta Interferon, Borna Disease Virus, Cytomegalovirus, Degenerative Disease, Disease Association, Enterovirus, Epstein Barr virus, Hepatitis Virus, Herpes Simplex Virus, HIV Associated Dementia, Human, Immune System, Inflammation, Influenza Virus, Influenza Virus A H5N1, Mental Disease, Mental Disorders, Multiple Sclerosis, Nerve Cell Degeneration, Neurodegenerative Diseases, Nonhuman, Parkinson Disease, Pathophysiology, Picornavirus, Roseolovirus, Varicella Zoster Virus, Virology, Virus Infection, Virus Pathogenesis, Virus Transmission, West Nile Flavivirus}, pubstate = {published}, tppubtype = {article} } Neurodegenerative and neurobehavioral diseases may be caused by chronic and neuropathic viral infections and may result in a loss of neurons and axons in the central nervous system that increases with age. To date, there is evidence of systemic viral infections that occur with some neurodegenerative conditions such as Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis, multiple sclerosis, autism spectrum disorders, and HIV-associated neurocognitive disorders. With increasing lifespan, the incidence of neurodegenerative diseases increases consistently. Neurodegenerative diseases affect approximately 37 million people worldwide and are an important cause of mortality. In addition to established non-viral-induced reasons for neurodegenerative diseases, neuropathic infections and viruses associated with neurodegenerative diseases have been proposed. Neuronal degeneration can be either directly or indirectly affected by viral infection. Viruses that attack the human immune system can also affect the nervous system and interfere with classical pathways of neurodegenerative diseases. Viruses can enter the central nervous system, but the exact mechanism cannot be understood well. Various studies have supported viral- and non-viral-mediated neurodegeneration at the cellular, molecular, genomic and proteomic levels. The main focus of this review is to illustrate the association between viral infections and both neurodegenerative and neurobehavioral diseases, so that the possible mechanism and pathway of neurodegenerative diseases can be better explained. This information will strengthen new concepts and ideas for neurodegenerative and neurobehavioral disease treatment. © 2014 Bentham Science Publishers. |
2012 |
Cheah, P -S; Ramshaw, H S; Thomas, P Q; Toyo-Oka, K; Xu, X; Martin, S; Coyle, P; Guthridge, M A; Stomski, F; Buuse, Van Den M; Wynshaw-Boris, A; Lopez, A F; Schwarz, Q P Neurodevelopmental and neuropsychiatric behaviour defects arise from 14-3-3ζ deficiency Journal Article Molecular Psychiatry, 17 (4), pp. 451-466, 2012, ISSN: 13594184, (cited By 58). Abstract | Links | BibTeX | Tags: 14-3-3 Proteins, Animal Experiment, Animal Model, Animal Tissue, Animals, Article, Autism, Behaviour Disorder, Bipolar Disorder, Brain, Cell Movement, Cells, Cognitive Defect, Controlled Study, Cultured, Disease Models, Disrupted in Schizophrenia 1 Protein, Embryo, Female, Gene, Gene Deletion, Genetic Predisposition to Disease, Glutamic Acid, Hippocampal Mossy Fiber, Hippocampus, Human, Hyperactivity, Inbred C57BL, Isoprotein, Knockout, Learning, Male, Maze Learning, Memory, Mice, Motor Activity, Mouse, Neurogenesis, Neuronal Migration Disorder, Neurons, Neuropsychiatry, Nonhuman, Priority Journal, Protein 14-3-3, Protein 14-3-3 Zeta, Protein Deficiency, Protein Interaction, Recognition, Risk Factor, Schizophrenia, Sensory Gating, Synapse, Unclassified Drug @article{Cheah2012451, title = {Neurodevelopmental and neuropsychiatric behaviour defects arise from 14-3-3ζ deficiency}, author = {P -S Cheah and H S Ramshaw and P Q Thomas and K Toyo-Oka and X Xu and S Martin and P Coyle and M A Guthridge and F Stomski and M Van Den Buuse and A Wynshaw-Boris and A F Lopez and Q P Schwarz}, url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-84859007028&doi=10.1038%2fmp.2011.158&partnerID=40&md5=7f507fef31a192a10b3cde7bf69b5442}, doi = {10.1038/mp.2011.158}, issn = {13594184}, year = {2012}, date = {2012-01-01}, journal = {Molecular Psychiatry}, volume = {17}, number = {4}, pages = {451-466}, abstract = {Complex neuropsychiatric disorders are believed to arise from multiple synergistic deficiencies within connected biological networks controlling neuronal migration, axonal pathfinding and synapse formation. Here, we show that deletion of 14-3-3ζ causes neurodevelopmental anomalies similar to those seen in neuropsychiatric disorders such as schizophrenia, autism spectrum disorder and bipolar disorder. 14-3-3ζ-Deficient mice displayed striking behavioural and cognitive deficiencies including a reduced capacity to learn and remember, hyperactivity and disrupted sensorimotor gating. These deficits are accompanied by subtle developmental abnormalities of the hippocampus that are underpinned by aberrant neuronal migration. Significantly, 14-3-3ζ- deficient mice exhibited abnormal mossy fibre navigation and glutamatergic synapse formation. The molecular basis of these defects involves the schizophrenia risk factor, DISC1, which interacts isoform specifically with 14-3-3ζ. Our data provide the first evidence of a direct role for 14-3-3ζ deficiency in the aetiology of neurodevelopmental disorders and identifies 14-3-3ζ as a central risk factor in the schizophrenia protein interaction network. © 2012 Macmillan Publishers Limited All rights reserved.}, note = {cited By 58}, keywords = {14-3-3 Proteins, Animal Experiment, Animal Model, Animal Tissue, Animals, Article, Autism, Behaviour Disorder, Bipolar Disorder, Brain, Cell Movement, Cells, Cognitive Defect, Controlled Study, Cultured, Disease Models, Disrupted in Schizophrenia 1 Protein, Embryo, Female, Gene, Gene Deletion, Genetic Predisposition to Disease, Glutamic Acid, Hippocampal Mossy Fiber, Hippocampus, Human, Hyperactivity, Inbred C57BL, Isoprotein, Knockout, Learning, Male, Maze Learning, Memory, Mice, Motor Activity, Mouse, Neurogenesis, Neuronal Migration Disorder, Neurons, Neuropsychiatry, Nonhuman, Priority Journal, Protein 14-3-3, Protein 14-3-3 Zeta, Protein Deficiency, Protein Interaction, Recognition, Risk Factor, Schizophrenia, Sensory Gating, Synapse, Unclassified Drug}, pubstate = {published}, tppubtype = {article} } Complex neuropsychiatric disorders are believed to arise from multiple synergistic deficiencies within connected biological networks controlling neuronal migration, axonal pathfinding and synapse formation. Here, we show that deletion of 14-3-3ζ causes neurodevelopmental anomalies similar to those seen in neuropsychiatric disorders such as schizophrenia, autism spectrum disorder and bipolar disorder. 14-3-3ζ-Deficient mice displayed striking behavioural and cognitive deficiencies including a reduced capacity to learn and remember, hyperactivity and disrupted sensorimotor gating. These deficits are accompanied by subtle developmental abnormalities of the hippocampus that are underpinned by aberrant neuronal migration. Significantly, 14-3-3ζ- deficient mice exhibited abnormal mossy fibre navigation and glutamatergic synapse formation. The molecular basis of these defects involves the schizophrenia risk factor, DISC1, which interacts isoform specifically with 14-3-3ζ. Our data provide the first evidence of a direct role for 14-3-3ζ deficiency in the aetiology of neurodevelopmental disorders and identifies 14-3-3ζ as a central risk factor in the schizophrenia protein interaction network. © 2012 Macmillan Publishers Limited All rights reserved. |
2011 |
Masuri, M G; Musa, N S; Isa, K A M The effects of animal assisted therapy in improving attention among autistic children Conference 2011, ISBN: 9781467300193, (cited By 0). Abstract | Links | BibTeX | Tags: Animals, Autism, Autistic Children, Behavioral Research, Children with Autism, Errors, Performance Tests, Sensory Integration, Student Performance, Students, Three Phasis @conference{Masuri2011813, title = {The effects of animal assisted therapy in improving attention among autistic children}, author = {M G Masuri and N S Musa and K A M Isa}, url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-84858995499&doi=10.1109%2fCHUSER.2011.6163849&partnerID=40&md5=1f29b24b9c2f78766401528f4e40a41d}, doi = {10.1109/CHUSER.2011.6163849}, isbn = {9781467300193}, year = {2011}, date = {2011-01-01}, journal = {2011 IEEE Colloquium on Humanities, Science and Engineering, CHUSER 2011}, pages = {813-818}, abstract = {Objective. This study examines the effect of Animal Assisted Therapy (AAT) towards improving attention among Autistic children. Method. A single case study using ABA design was used to measure duration of attention and errors omitted using Mesulam Continuous Performance Test (CPT) across three phases among 4 participants. Task Behavior/ Completion section in School Function Assessment (SFA) was given to teachers to rate student performance before and after intervention phase. Results. Results from this study showed that AAT did not improve attention and task behavior among 4 participants. However there is noted slight increase in attention among participants during the intervention phase. All participants also had slight decrease in attention during withdrawal phase. Decreases in numbers of errors omitted in CPM were noted in all participants during intervention phase. Conversely, all participants except participant 4 had increase in numbers of errors omitted during withdrawal phase. Result from Task behavior also showed no improvement. Conclusions. The findings from this study demonstrate that AAT did not improve attention and task behavior among Autistic children. However, the findings suggest that AAT can be one of treatment approach among Autistics children. Further study with longer timelines is needed to demonstrate a much better outcome as well as to ensure that the impact of the interventions really give an effect to the sample. © 2011 IEEE.}, note = {cited By 0}, keywords = {Animals, Autism, Autistic Children, Behavioral Research, Children with Autism, Errors, Performance Tests, Sensory Integration, Student Performance, Students, Three Phasis}, pubstate = {published}, tppubtype = {conference} } Objective. This study examines the effect of Animal Assisted Therapy (AAT) towards improving attention among Autistic children. Method. A single case study using ABA design was used to measure duration of attention and errors omitted using Mesulam Continuous Performance Test (CPT) across three phases among 4 participants. Task Behavior/ Completion section in School Function Assessment (SFA) was given to teachers to rate student performance before and after intervention phase. Results. Results from this study showed that AAT did not improve attention and task behavior among 4 participants. However there is noted slight increase in attention among participants during the intervention phase. All participants also had slight decrease in attention during withdrawal phase. Decreases in numbers of errors omitted in CPM were noted in all participants during intervention phase. Conversely, all participants except participant 4 had increase in numbers of errors omitted during withdrawal phase. Result from Task behavior also showed no improvement. Conclusions. The findings from this study demonstrate that AAT did not improve attention and task behavior among Autistic children. However, the findings suggest that AAT can be one of treatment approach among Autistics children. Further study with longer timelines is needed to demonstrate a much better outcome as well as to ensure that the impact of the interventions really give an effect to the sample. © 2011 IEEE. |
2007 |
Pandi-Perumal, S R; Srinivasan, V; Spence, D W; Cardinali, D P Role of the melatonin system in the control of sleep: Therapeutic implications Journal Article CNS Drugs, 21 (12), pp. 995-1018, 2007, ISSN: 11727047, (cited By 90). Abstract | Links | BibTeX | Tags: Absence of Side Effects, Acetylserotonin Methyltransferase, Advanced Sleep Phase Syndrome, Agomelatine, Alpha Tocopherol, Alzheimer Disease, Animals, Ascorbic Acid, Beta Adrenergic Receptor Blocking Agent, Biosynthesis, Circadian Rhythm, Circadian Rhythm Sleep Disorder, Clinical Trial, Confusion, Delayed Sleep Phase Syndrome, Drowsiness, Drug Dose Comparison, Drug Efficacy, Drug Half Life, Drug Mechanism, Fatigue, Fluvoxamine, Headache, Hormone Metabolism, Human, Hypnosis, Hypothalamus, Insomnia, Jet Lag, Macaca, Melatonin, Melatonin Receptor, Muscle Cramp, Nausea, Non-24-Hour Sleep-Wake Syndrome, Nonhuman, Noradrenalin, Pineal Body, Priority Journal, Protein Expression, Ramelteon, Rat Strain, Receptor Density, Receptors, REM Sleep, Retina Ganglion Cell, Review, Serotonin, Shift Worker, Sleep, Sleep Disorder, Sleep Waking Cycle, Smith Magenis Syndrome, Suprachiasmatic Nucleus, Sustained Drug Release, Vomiting @article{Pandi-Perumal2007995, title = {Role of the melatonin system in the control of sleep: Therapeutic implications}, author = {S R Pandi-Perumal and V Srinivasan and D W Spence and D P Cardinali}, url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-36248949004&doi=10.2165%2f00023210-200721120-00004&partnerID=40&md5=489ee976fa444beb95b26cdb77b722c2}, doi = {10.2165/00023210-200721120-00004}, issn = {11727047}, year = {2007}, date = {2007-01-01}, journal = {CNS Drugs}, volume = {21}, number = {12}, pages = {995-1018}, abstract = {The circadian rhythm of pineal melatonin secretion, which is controlled by the suprachiasmatic nucleus (SCN), is reflective of mechanisms that are involved in the control of the sleep/wake cycle. Melatonin can influence sleep-promoting and sleep/wake rhythm-regulating actions through the specific activation of MT1 (melatonin 1a) and MT2 (melatonin 1b) receptors, the two major melatonin receptor subtypes found in mammals. Both receptors are highly concentrated in the SCN. In diurnal animals, exogenous melatonin induces sleep over a wide range of doses. In healthy humans, melatonin also induces sleep, although its maximum hypnotic effectiveness, as shown by studies of the timing of dose administration, is influenced by the circadian phase. In both young and elderly individuals with primary insomnia, nocturnal plasma melatonin levels tend to be lower than those in healthy controls. There are data indicating that, in affected individuals, melatonin therapy may be beneficial for ameliorating insomnia symptoms. Melatonin has been successfully used to treat insomnia in children with attention-deficit hyperactivity disorder or autism, as well as in other neurodevelopmental disorders in which sleep disturbance is commonly reported. In circadian rhythm sleep disorders, such as delayed sleep-phase syndrome, melatonin can significantly advance the phase of the sleep/wake rhythm. Similarly, among shift workers or individuals experiencing jet lag, melatonin is beneficial for promoting adjustment to work schedules and improving sleep quality. The hypnotic and rhythm-regulating properties of melatonin and its agonists (ramelteon, agomelatine) make them an important addition to the armamentarium of drugs for treating primary and secondary insomnia and circadian rhythm sleep disorders. © 2007 Adis Data Information BV. All rights reserved.}, note = {cited By 90}, keywords = {Absence of Side Effects, Acetylserotonin Methyltransferase, Advanced Sleep Phase Syndrome, Agomelatine, Alpha Tocopherol, Alzheimer Disease, Animals, Ascorbic Acid, Beta Adrenergic Receptor Blocking Agent, Biosynthesis, Circadian Rhythm, Circadian Rhythm Sleep Disorder, Clinical Trial, Confusion, Delayed Sleep Phase Syndrome, Drowsiness, Drug Dose Comparison, Drug Efficacy, Drug Half Life, Drug Mechanism, Fatigue, Fluvoxamine, Headache, Hormone Metabolism, Human, Hypnosis, Hypothalamus, Insomnia, Jet Lag, Macaca, Melatonin, Melatonin Receptor, Muscle Cramp, Nausea, Non-24-Hour Sleep-Wake Syndrome, Nonhuman, Noradrenalin, Pineal Body, Priority Journal, Protein Expression, Ramelteon, Rat Strain, Receptor Density, Receptors, REM Sleep, Retina Ganglion Cell, Review, Serotonin, Shift Worker, Sleep, Sleep Disorder, Sleep Waking Cycle, Smith Magenis Syndrome, Suprachiasmatic Nucleus, Sustained Drug Release, Vomiting}, pubstate = {published}, tppubtype = {article} } The circadian rhythm of pineal melatonin secretion, which is controlled by the suprachiasmatic nucleus (SCN), is reflective of mechanisms that are involved in the control of the sleep/wake cycle. Melatonin can influence sleep-promoting and sleep/wake rhythm-regulating actions through the specific activation of MT1 (melatonin 1a) and MT2 (melatonin 1b) receptors, the two major melatonin receptor subtypes found in mammals. Both receptors are highly concentrated in the SCN. In diurnal animals, exogenous melatonin induces sleep over a wide range of doses. In healthy humans, melatonin also induces sleep, although its maximum hypnotic effectiveness, as shown by studies of the timing of dose administration, is influenced by the circadian phase. In both young and elderly individuals with primary insomnia, nocturnal plasma melatonin levels tend to be lower than those in healthy controls. There are data indicating that, in affected individuals, melatonin therapy may be beneficial for ameliorating insomnia symptoms. Melatonin has been successfully used to treat insomnia in children with attention-deficit hyperactivity disorder or autism, as well as in other neurodevelopmental disorders in which sleep disturbance is commonly reported. In circadian rhythm sleep disorders, such as delayed sleep-phase syndrome, melatonin can significantly advance the phase of the sleep/wake rhythm. Similarly, among shift workers or individuals experiencing jet lag, melatonin is beneficial for promoting adjustment to work schedules and improving sleep quality. The hypnotic and rhythm-regulating properties of melatonin and its agonists (ramelteon, agomelatine) make them an important addition to the armamentarium of drugs for treating primary and secondary insomnia and circadian rhythm sleep disorders. © 2007 Adis Data Information BV. All rights reserved. |